Public Cancer Research, Private Cancer Profits: The Taxpayer Paid Twice
I followed the Taxol invoice, and the handwriting gets suspiciously fancy near the bottom. Publicly supported NIH research helped carry the scientific risk behind paclitaxel, while Bristol Myers Squibb became the name attached to the commercial blockbuster. The exact accounting deserves careful checking, but the central complaint is hard to miss: shared research can become private revenue before the public gets a meaningful return.
That is the pharmaceutical business model in a lab coat. Taxpayers help finance the runway, private interests get the applause, and patients are handed the receipt for progress they helped make possible. Nobody objects to a company earning money by bringing a treatment to patients; the question is why public investment so often exits through the front door while public accountability is left waiting in the lobby. Follow the invoice long enough and “research for all” can end with profits for the private and a second bill for the sick.